Dear Editor,Lung cancer is the predominant cause of cancer-related deaths globally,with non-small cell lung cancer(NSCLC)accounting for 85%of all cases.1 The five-year overall survival(OS)after surgery remains poor be...Dear Editor,Lung cancer is the predominant cause of cancer-related deaths globally,with non-small cell lung cancer(NSCLC)accounting for 85%of all cases.1 The five-year overall survival(OS)after surgery remains poor because of the high rate of postoperative recurrence and metastasis.Recently,immune checkpoint inhibitors(ICIs)have shown promising efficacy in resectable NSCLC.展开更多
基金supported by grants from the National Natural Science Foundation of China (81472640,81672802,82273268)the Zhejiang Provincial Natural Science Foundation of China (No.LZ17H160004)+2 种基金the Key R&D Program of Zhejiang (2022C03100)the Zhejiang Provincial Program for the Cultivation of High-Level Innovative Health Talentsthe Leading Innovative and Entrepreneur Team Introduction Program of Zhejiang (2019R01007).
文摘Dear Editor,Lung cancer is the predominant cause of cancer-related deaths globally,with non-small cell lung cancer(NSCLC)accounting for 85%of all cases.1 The five-year overall survival(OS)after surgery remains poor because of the high rate of postoperative recurrence and metastasis.Recently,immune checkpoint inhibitors(ICIs)have shown promising efficacy in resectable NSCLC.
